Navigation Links
Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
Date:2/11/2008

ate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, competitive offerings, product performance and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward- looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expe
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007
2. Boston Scientific to Participate in Merrill Lynch Conference
3. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
4. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
5. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
6. Boston Scientific Announces Results for Third Quarter Ended September 30, 2007
7. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
8. The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Nov. 2-6
9. Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator
10. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
11. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Quincy, MA (PRWEB) September 02, 2014 ... announced today the signage of a distribution agreement ... Azelis is now distributing Myriant’s bio-succinic acid in ... Kingdom and Ireland, targeting customers in the industrial ... chemical distribution powerhouse, Azelis offers a far-reaching chemical ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... today positive results from its final preclinical toxicology ... Administration (FDA) guidance, this bridging study was required ... candidate designed to prevent the devastating effects of ...
(Date:9/2/2014)... The inventors of tinAway, a novel treatment ... seeking support for development costs through a crowdfunding campaign. ... ), was launched on September 1, 2014. , tinAway ... is based on ten years of neuroscience research. ... software engineers, Dr. Ian Dixon and Mr. Tony Burgess, ...
(Date:8/31/2014)... 2014 Available spectra is similar ... research and cultivation of a wide range of ... LEDs with proven patented and pending wide spectrum ... uniformity in critical applications in contrast to growth ... “Our customers have a large variety of differently ...
Breaking Biology Technology:Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... breed of pea seeds has been created that contains ... that attacks chickens. Researchers writing in the open access ... the GM seeds, and demonstrate their effectiveness in preventing ... a team of researchers from Novoplant GmbH, Germany, to ...
... , , HONG KONG, Sept. ... safe in patients who need coronary revascularization before undeferrable non-cardiac ... a paper published online in the International Journal of ... of print]). , , The paper, titled ...
... , LYNBROOK, N.Y., Sept. 11 BioSpecifics Technologies ... first in class collagenase-based products, today announced that BioSpecifics, President, ... the Biotech Industry" Conference on Wednesday, September 16, 2009, at ... Center in New York, NY. , , ...
Cached Biology Technology:OrbusNeich's Genous(TM) Bio-engineered R stent(TM) is Feasible in Patients Requiring Undeferrable Non-Cardiac Surgery, International Journal of Cardiology Publication Reports 2
(Date:9/2/2014)... study published in the September 2014 issue of ... Child and Adolescent Psychiatry found that children ... an increased risk of developing diabetes if they ... the nationwide Danish registers, a group of researchers ... University Hospital, Denmark, studied 48,299children and adolescents with ...
(Date:9/2/2014)... limestone is well known as a result of ... (for example, Archaeopteryx). Now, for the first time, ... equivalent of these outcrops - discoveries which include ... treader. , Despite the abundance of fossils in ... obtained from the Late Kimmeridgian equivalents of these ...
(Date:9/1/2014)... has improved steadily in recent yearsspurred in large part ... poor and disparities continue to widen among socioeconomic and ... School of Public Health (HSPH). , "The study provides ... efforts by many groups and individuals to improve U.S. ... indicates that these efforts need to be expanded," said ...
Breaking Biology News(10 mins):Risk of diabetes in children and adolescents exposed to antipsychotics 2Exceptionally well preserved insect fossils from the Rhône Valley 2Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3
... A spoonful of medicine goes down a lot easier if ... helpful for women living with HIV/AIDS and managing their chronic ... Bolton School of Nursing at Case Western Reserve University. ... managing other chronic illnesses," said Allison R. Webel, instructor of ...
... Ill. Land and marine iguanas and giant tortoises ... the Galpagos islands are more likely to harbor antibiotic-resistant ... sites on the islands, researchers report in a ... sites from free-living reptiles harbored Escherichia coli ...
... release is available in Spanish . ... because of their characteristics, produce a certain amount of social ... fact that they are subjected to moral conflicts and ethical ... very necessary from a social perspective, as in the case ...
Cached Biology News:CWRU study finds the love of a dog or cat helps women cope with HIV/AIDS 2Patterns of antibiotic-resistant bacteria found in Galapagos reptiles 2Moral imagination as a key to overcoming work-related stigmas 2
ssDNA from PCR DNA in less than 1 hour. No gels, columns, or slurries. Sequence from high quality ssDNA: clearer reads, longer runs....
... Freezerworks Unlimited includes 2 clients and streamlines sample ... sharing of freezers by multiple groups without the ... Network Client/Server version for Macintosh ... with 256 colors; OS 8.6 & OS 9.x ...
Applications: Immunohistochemistry, ISH, FISH, CISH....
... Amplification Kit, 500 reactions. Prepare circular ... 4-6 h.Generate microgram quantities of template ... material.Use amplified DNA directly for cycle ... or M13 liquid cultures, colonies, plaques, ...
Biology Products: